The efficacy of a 5-day treatment with coumermycin Al (hereafter referred to as coumermycin) ( 
ciprofloxacin was as effective as cloxacillin plus gentamicin. Coumermycin plus ciprofloxacin was less effective than ciprofloxacin alone (P = 0.01). For endocarditis induced by two additional methicillin-susceptible S. aureus strains, the high-dosage regimen of coumermycin (12 mg/kg every 12 h) had the same low efficacy. Coumermycin-resistant variants of S. aureus emerged in most of the vegetations during coumermycin treatment. The ciprofloxacin susceptibility of S. aureus was unchanged during ciprofloxacin treatment. The addition of ciprofloxacin to coumermycin in the treatment did not prevent the emergence of coumermycinresistant variants. Twelve additional S. aureus strains isolated from the blood of patients with endocarditis were tested in vitro against coumermycin with precautions to avoid carry-over of the antibiotic. Coumermycin exhibited a bacteriostatic activity at very low concentrations (MIC, <0.004 ,ug/ml) but only a weak bactericidal activity (MBC for 90% of strains, 8 ,ug/ml), a finding contrasting with that of others. Furthermore, coumermycin-resistant mutants could be selected in vitro from the 15 S. aureus strains tested. These results indicated no evidence in vivo of a synergistic activity of coumermycin and ciprofloxacin. More importantly, these results suggested that coumermycin might not be adequate for the treatment of serious S. aureus infections in humans.
Coumermycin Al (hereafter referred to as coumermycin) is a bis-hydroxycoumarin antibiotic structurally related to novobiocin and isolated from Streptomyces rishiriensis (3, 15) . Its bacterial target is the B subunit of DNA-gyrase (8, 13) . In vitro, a high antibacterial activity is demonstrated by coumerriycin against some gram-positive organisms, especially staphylococci. The MIC of coumermycin for methicillin-susceptible or methicillin-resistant Staphylococcus aureus is usually lower than the MICs of the other antistaphylococcal antibiotics. Furthermore, in microdilution procedures, the MBC has been described as being very close to the MIC (1, 6, 9-11, 16, 17) . In vivo, preliminary studies in mice suggest that coumermycin has a good protective activity against S. aureus infections (10, 15; J. Unowski, personal communication).
The newly developed fluoroquinolone compounds are active against S. aureus (19, 21) , and since their bacterial target is the A subunit of DNA-gyrase (13, 22) , it has been suggested and shown in vitro that these substances might act synergistically with coumermycin against gram-positive bacteria (17) .
The purpose of the present study was to investigate in rats the activity of coumermycin and that of a fluoroquinolone, ciprofloxacin (1, 4, 5) , in a model of left-sided endocarditis induced by S. aureus. This model of experimental endocarditis is a stringent test of antibiotic bactericidal activity, since the polymorphonuclear leukocytes have limited access to the bacteria embedded in the valvular vegetations (7) . Because of the low therapeutic efficacy of coumermycin in endocarditis induced by one S. aureus * Corresponding author. strain, we further evaluated its activity in endocarditis induced by two additional strains of S. aureus. As we obtained similar results, we compared in vitro the susceptibilities to bacterial killing by coumermycin of these 3 strains with the susceptibilities of 12 additional strains of S. aureus isolated from patients with endocarditis.
(This paper was presented in part at the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, Minn. [C. Perronne, R. Malinverni, and M. P. Glauser, Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 473A, 1985] .) MATERIALS AND METHODS Experimental strains. The 15 strains of S. aureus studied were isolated from the blood of patients with staphylococcal endocarditis.
One methicillin-susceptible strain of S. aureus, coded strain 1112, was used to induce endocarditis. This strain has been previously evaluated in this model (2) . We examined the therapeutic efficacies of coumermycin, of ciprofloxacin, and of their combination and compared them with that of the cloxacillin-gentamicin combination that has exhibited the best efficacy against this strain in this model (2) .
Two additional methicillin-susceptible strains of S. aureus, coded strain 7 and strain 560, were used to induce endocarditis to test further the therapeutic efficacy of coumermycin. (10-and 100-fold) of this concentrate (containing 109 and 108 CFU/ml, respectively) were prepared by dilution in normal saline. A 0.1-ml sample from each bacterial suspension was plated onto Mueller-Hinton agar containing either no antibiotic or 0.4 jig of coumermycin per ml, a concentration 100-fold the MIC. The ratio of the number of colonies appearing on plates with and without antibiotic after 48 h of incubation was taken as an estimate of the frequency of bacteria resistant to a coumermycin concentration 100-fold the MIC (13) . The results were expressed as the mean of three experiments.
Production of endocarditis. Sterile vegetations were produced in female Wistar rats (200 to 220 g) by insertion of a polyethylene catheter across the aortic valve through the right carotid artery as previously described (12) . The catheter was secured with a silk ligature and left in place throughout the experiments. At 24 h after catheterization, rats were injected in the tail vein with 0.5 ml of a suspension prepared from an overnight culture of S. aureus to contain approximately 106 CFU/ml.
Since we have previously shown in this model of staphylococcal endocarditis that without antibiotic treatment, infection invariably leads to death of the rats within 3 days after bacterial challenge (2) , no placebo-treated control rats were used in the present experiments. At the beginning of treatment (i.e., 24 h after bacterial challenge), rats were randomized either to be sacrificed to determine the incidence and the severity of infection (as measured by the CFU per gram of vegetations) or to receive 5 days of antibiotic treatment.
Treatment regimens. Rats infected with S. aureus 1112 and randomized for treatment received coumermycin at three different dosages, ciprofloxacin, the coumermycinciprofloxacin combination, or the reference treatment consisting of the cloxacillin-gentamicin combination. The three coumermycin dosage regimens studied were as follows: 4 mg/kg every 24 h (q 24 h), 4 mg/kg q 12 h, or 12 mg/kg q 12 h. Coumermycin was solubilized in a solvent (containing 11% alcohol [USPI, 20o propylene glycol, 1% benzyl alcohol, and water [as much as suffices]) before further dilution in water and subcutaneous (s.c.) injection. The ciprofloxacin dosage regimen was 30 mg/kg q 8 h given s.c., either alone or in comnbination with coumermycin at a dosage of 4 mg/kg q 24 h. For the cloxacillin-gentamicin treatment, cloxacillin was injected s.c. at a dosage of 200 mg/kg q 8 h, and gentamicin was injected intramuscularly at a dosage of 4 mg/kg q 8 h.
Rats infected with S. aureus 7 or S. aureus 560 received only the high-dosage regimen of coumermycin (i.e., 12 mg/kg s.c. q 12 h). The therapeutic results were compared with those obtained with the same dosage regimen in endocarditis induced by strain 1112.
Evaluation of infection. The control rats were sacrificed 24 h after bacterial challenge. The treated rats were sacrificed after 5 days of antibiotic treatment (8 h after the last injections of ciprofloxacin and of cloxacillin-gentamicin and 24 h after the last injections of coumermycin and of coumermycin-ciprofloxacin. Blood (1 ml) was drawn from the inferior vena cava, plated onto Columbia blood agar, and incubated for colony counts. Aortic vegetations were excised aseptically, weighed, homogenized in 1 ml of saline, serially diluted, and plated onto Columbia blood agar. Colonies were counted after 24 h of incubation at 37°C, and the colony counts for each rat were expressed in log1o CFU per gram of vegetations. Rats that died during treatment were refrigerated at 4°C within 6 h of death; blood was not cultured from these animals, but their vegetations were processed as described above. Since death occurred at various times during treatment, individual bacterial densities of the vegetations of dying animnals were not taken into account for comparison of the activity of the various antibiotic regimens.
Aliquots of vegetation homogenates from control and treated rats were routinely used for coumermycin and ciprofloxacin MIC determinations. The MICs were compared with the MIC for the bacteria contained in the inoculum used for challenge.
Antibiotic levels in serum in normal and infected rats. ,ug/ml, those of ciprofloxacin were 0.25 and 2 jig/ml, those of cloxacillin were 0.125 and 0.5 jig/ml, and those of gentamicin were 0.125 and 1 ,ug/ml. Thus, for strain 1112 the MBC/MIC ratio of coumermycin was high (equal to 250), but this was not the case with ciprofloxacin, cloxacillin, and gentamicin. The time-kill curves of strain 1112 in the presence of coumermycin and of ciprofloxacin are shown in Fig. 1 . Coumermycin at a concentration as high as 250 times the MIC was bactericidal only during the first 6 h of incubation; ciprofloxacin at a concentration as high as 20 times the MIC was moderately bactericidal only during the first 2 h of incubation. The coumermycin-ciprofloxacin combination exhibited an increased activity over that observed with either single drug only after 48 h of incubation. For strain 1112, the frequency of bacteria resistant to a concentration of coumermycin 100-fold the MIC was 5 x 10-'. Susceptibility tests of S. aureus 7 and 560. For both strains, the MIC of coumermycin was <0.004 pLg/ml, while the MBCs were 8 ,ug/ml for strain 7 and 4 jig/ml for strain 560; thus, the MBC/MIC ratios were 2,000 and 1,000, respectively. The time-kill curves with coumermycin were similar to those of strain 1112 (data not shown). The frequencies of bacteria resistant to a concentration of coumermycin 100-fold the MIC were 5 x 10-' for strain 7 and 3 x 10-9 for strain 560.
Antibiotic levels in serum in normal rats. Levels of coumermycin and of ciprofloxacin in serum in normal rats are shown in Fig. 2 Table 2 . The three coumermycin regimens were less effective than the cloxacillin-gentamicin combination in sterilizing the vegetations (P < 0.05) and in reducing the bacterial counts in the vegetations (P < 10-8). In contrast, the ciprofloxacin treatment was as good as the cloxacillin-gentamicin treatment with respect to cumulative mortality, sterilization of the vegetations, and reduction of the bacterial counts in the vegetations. With regard to combined coumermycin-ciprofloxacin treatment, cumulative mortality and sterilization of the vegetations were not significantly different from those observed after ciprofloxacin monotherapy. However, the coumermycinciprofloxacin combination was less effective in reducing the bacterial counts than the cloxacillin-gentamicin combination (P = 10-') or ciprofloxacin alone (P = 0.01).
The MIC of coumermycin for the bacteria recovered from all the control rats was identical to the MIC for the original inoculum (<0.004 jig/ml), but the MIC of coumermycin for the bacteria recovered from 56 of 73 (77%) rats treated with coumermycin was increased, ranging from 0.008 to 2 ,ug/ml. Among these S. aureus variants less susceptible to coumermycin, the MIC for 46 of 56 (82%) rats ranged from 0.25 to 2 p.g/ml (i.e., from 62 times the MIC to 500 times the MIC). The addition of ciprofloxacin to coumermycin for treatment did not prevent the emergence of such coumermycin-resistant variants, since the MIC of coumermycin for the bacteria recovered from all the rats treated with the coumermycin-ciprofloxacin combination was increased, ranging from 0.25 to 0.5 ,ug/ml (i.e., from 62 times the MIC to 124 times the MIC). The MIC of ciprofloxacin for the bacteria recovered from the rats treated with ciprofloxacin was unchanged.
Efficacy of the high-dosage regimen of coumermycin against endocarditis induced by S. aureus 7 and 560. The results of testing the high-dosage regimen of coumermycin against endocarditis induced by strains 7 and 560 are reported in Table 3 and are compared with the results of testing the same regimen against endocarditis induced by strain 1112. The cumulative mortality, the rate of sterilization of the vegetations, and the reduction of the bacterial counts in the vegetations were not significantly different for the three strains. The MIC of coumermycin for the bacteria recovered from all the control rats was identical to the MIC for the original inocula (<0.004 ,ug/ml), but the MIC of coumermycin for the bacteria recovered from all the treated rats ranged from 0.25 to 8 ,ug/ml (i.e., from 62 times the MIC to 2,000 times the MIC).
Susceptibility tests of the 12 additional strains of S. aureus. Because coumermycin had a low therapeutic efficacy, we tested the susceptibility to killing of 12 additional strains of S. aureus, using precautions to avoid the carry-over of antibiotic. For all strains, the MIC of coumermycin was <0.004 ,ug/ml. The MBCs ranged from 0.032 to 8 ,ug/ml, the MBC for 50% of the strains being 4 jxg/ml and the MBC for 90% of the strains being 8 ,ug/ml. For 1 strain, the MBC/MIC ratio was 8; for the 11 remaining strains, the MBC/MIC ratio ranged from 125 to 2,000. Thus, these results are in disagreement with those of other studies (1, 6, 9-11, 16, 17) which tested the MBC of coumermycin for S. aureus but did not consider the carry-over phenomenon. The frequency of bacteria resistant to a concentration of coumermycin 100-fold the MIC ranged from 2.7 x 10-9 to 3.1 x 10-8.
DISCUSSION
In this experimental model of endocarditis, three coumermycin dosage regimens were far less effective than the cloxacillin-gentamicin combination in reducing the bac- terial counts in the cardiac vegetations of rats infected with one strain of S. aureus. This low therapeutic efficacy of coumermycin was confirmed in endocarditis caused by two additional strains of S. aureus. In contrast to coumermycin, ciprofloxacin, which is also a DNA-gyrase inhibitor (8, 13, 22) , was as effective as the cloxacillin-gentamicin combination in the treatment of endocarditis caused by one strain of S. aureus. These good therapeutic results of ciprofloxacin are in accordance with those obtained with another fluoroquinolone, pefloxacin, in the treatment of staphylococcal endocarditis in rabbits (19) . The coumermycin-ciprofloxacin combination was less effective than ciprofloxacin alone in reducing the bacterial counts in the vegetations.
The low therapeutic efficacy of coumermycin in S. aureus endocarditis was observed despite coumermycin levels in serum 3-fold to 24-fold the MBC for the infecting strains at the peak and 1.6-fold to 13-fold the MBC at the trough on day 5 of the high-dosage regimen. This limited efficacy of coumermycin may have been due to several reasons. First, the determination of the MBCs for 15 S. aureus strains isolated from patients with staphylococcal endocarditis suggests that coumermycin has a limited bactericidal activity. Because of the extremely high growth-inhibiting activity of coumermycin on S. aureus (1, 6, 9-11, 16, 17) , the determination of its bactericidal effect is difficult, since the antibiotic carry-over may impede the growth of surviving bacteria. This phenomenon leads to an underestimation of MBCs and an overestimation of the bactericidal effects of the drug in time-kill curves. Second, the selection during treatment of variants less susceptible or resistant to coumermycin may also be partly responsible for the therapeutic failure of coumermycin. The addition of ciprofloxacin to coumermycin in the treatment did not prevent the emergence of such coumermycin-resistant variants. Mutants less susceptible to coumermycin could be selected in vitro from all 15 S. aureus strains tested. Third, it has been found in vitro that coumermycin may be inactivated by serum or blood (6, 15) , but the relevance of this phenomenon has not been studied so far. It is conceivable that it may have accounted somewhat for the limited efficacy observed in the present experiments. Fourth, the penetration of coumermycin into cardiac vegetations is unknown, but because the drug is a large molecule with a molecular weight of 1,106 (13), it might be low.
The therapeutic failure of coumermycin in our model of staphylococcal endocarditis is in contrast to the good protective activity of coumermycin already described in models of thigh or peritoneum staphylococcal infections in mice (10, 15; J. Unowski, personal communication). Since coumermycin was injected at the time of bacterial challenge in these protection models, the bacterial load at the start of treatment was considerably lower than after 24 h of systemic infection, as in our endocarditis model.
The good therapeutic efficacy of ciprofloxacin in S. aureus endocarditis was observed at ciprofloxacin levels in serum 2.3-fold the MBC for the infecting strain at the peak and 0.3-fold the MBC at the trough. The susceptibility of the bacteria to ciprofloxacin was not modified during treatment.
In conclusion, coumermycin, despite its very high bacteriostatic activity in vitro, was disappointing in the treatment of experimental S. aureus endocarditis. This model requires a bactericidal activity of the therapeutic agent because the bacterial load is high and because the catheter is left in place throughout the experiments, mimicking prosthetic valve endocarditis. Ciprofloxacin exhibited a high antistaphylococcal activity in the same model, but its combination with coumermycin reduced its therapeutic efficacy. Coumermycin will not be developed further for clinical use (M. Fernex, personal communication).
